In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From LaNova Medicines

BMS Bets $8.4bn On Biokin’s Bispecific ADC

In a record licensing deal involving a single biopharma asset from China, Biokin and its US subsidiary SystImmune will receive up to $8.4bn from BMS, including $800m upfront, for a bispecific ADC with broad oncology potential. 

China Deals

Pentavalent Meningococcal Vaccine Among Latest EU Filings

Marketing applications for MenABCWY, zolbetuximab, crovalimab, macitentan/tadalafil, Coacillium, mRNA-1345, dasiglucagon and ustekinumab have been submitted to the European Medicines Agency for review.

Drug Review Europe

Unthinkable? Reports That AZ May Spin Off China Ops Amid Geopolitical Risks

AstraZeneca is reportedly considering joining a prominent investment fund to spin off and list its Chinese entities, in an apparent bid to better insulate them against potential geopolitical risks.

China Business Strategies

Asia Deal Watch: HanAll, Daewoong Team With US Biotech In Parkinson's

Sino acquires Gmax's obesity drug candidate. Simcere partners with Mass General Brigham on select research projects.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register